Guess which ASX All Ords share just crashed 52% on a TGA update

Today was a day that shareholders of this medical diagnostics technology company won't forget in a hurry.

| More on:
A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This medical diagnostics technology company was sold off on Monday
  • This follows news that its TGA application for ColoSTAT has been withdrawn
  • ColoSTAT is a simple, low-cost, blood test for global mass market detection of colorectal cancer

The Rhythm Biosciences Ltd (ASX: RHY) share price had a day to forget on Monday.

The medical diagnostics technology's shares returned from a trading halt and crashed as much as 52% to 46 cents.

The ASX All Ords share ultimately recovered a touch and ended the day with a 38% decline to 59.5 cents.

Why did this ASX All Ords share get hammered?

Investors were hitting the sell button in a panic on Monday after the company was dealt a blow by the Australian Therapeutic Goods Administration (TGA).

According to an announcement, after the receipt and analysis of a thorough application review and its most recent engagement with the TGA, the company has decided to withdraw its current ColoSTAT application for an Australian Register of Therapeutic Goods (ARTG) listing.

Rhythm Biosciences' ColoSTAT product is a simple, low-cost, blood test for global mass market detection of colorectal cancer. It notes that worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

Management advised that it is withdrawing its application because it simply does not have enough time to answer the regulator's questions within the necessary timeframe. This is because some questions will require new internal analytical testing and the TGA is reluctant to provide an extension beyond its 20 business days timeframe.

The good news is that this isn't the end of the road for ColoSTAT in Australia. Management intends to submit a new application with the TGA, in line to better meet their feedback and questions posed.  And while the company doesn't know when the new application will be submitted, it does expect it to be in the current calendar year.

Furthermore, this withdrawal does not impede the ASX All Ords share's proposed market entry activities into other CE Mark conforming territories and additional international markets, including the United States.

Management commentary

Rhythm Biosciences' Executive Chairman, Otto Buttula, was disappointed but remains positive on the future. Buttula said:

Having decided to withdraw RHY's current TGA submission for ColoSTAT is clearly disappointing for all stakeholders. Nonetheless, we appreciate the thorough review undertaken and meaningful dialogue with the TGA. Following the TGA's most recent feedback, both written and verbal and management / Board review, we believe that time constraints imposed result in a better opportunity for the Company to submit a new and strengthened application, in line with the questions raised in the TGA application review. Hence, with a new submission to be completed in line with the questions raised by the TGA, we believe we have a better blueprint to follow in framing our new application.

Therefore, I remain confident of a TGA registration for ColoSTAT in the future. Whilst Australia, as our home, remains important, it represents one of the smaller markets in our global aspirations and the Company has always intended to build the majority of its revenues in overseas territories. We look forward to keeping the market abreast of other positive developments in the near term.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Young man with a laptop in hand watching stocks and trends on a digital chart.
Share Market News

Which investment trends drove equity markets in May according to Macquarie?

The ASX 200 increased 4.2% in May.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Opinions

Too high? These 2 ASX shares might be due for a correction

These popular blue chips are looking dicey to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Why Clarity, Coronado Global, Iperionx, and Lynas shares are roaring higher today

These shares are having a strong session on Thursday. Why are investors buying them?

Read more »